DOI: https://doi.org/10.14710/jbtr.v9i2.16293

Increased Level of The Plasminogen Activator Inhibitor Type-1 is Associated with Severity of NAFLD

1Gastroentero-Hepatology Division, Department of Internal Medicine, Dr Kariadi Hospital, Indonesia

2Faculty of Medicine, Universitas Diponegoro, Indonesia

Received: 28 Oct 2022; Revised: 13 Apr 2023; Accepted: 17 May 2023; Available online: 31 Aug 2023; Published: 31 Aug 2023.
Open Access Copyright (c) 2023 Journal of Biomedicine and Translational Research
Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

Background: Non-Alcoholic Fatty Liver Disease (NAFLD) has been the most common cause of chronic liver disease worldwide. In NAFLD, elevated Plasminogen Activator Inhibitor-1 (PAI-1) is associated with risk factors for thrombosis and hypercoagulable state.

Objective: This study explored the relationship between NAFLD as an independent factor for increasing PAI-1 in the presence of metabolic syndrome and insulin resistance.

Methods: This observational study used a cross-sectional design with 80 subjects including 40 patients with NAFLD and 40 without NAFLD at dr. Kariadi Semarang who met the inclusion and exclusion criteria. Measurement of plasma PAI-1 levels was done using ELISA method.

Results: A total of 80 patients were included. In the case group, based on abdominal ultrasound, NAFLD was mostly found in the mild category (86%), while the rest were moderate (10%), and severe (4%). Only 25% were found in the Simple Steatosis category, and 75% were suspected of having NASH (NAS = 3-4) and NASH (NAS > 5). There was a significant difference between plasma PAI-1 level and the incidence of NAFLD (p = 0.011). The mean PAI-1 level between the three NAFLD severity categories also shown a significant difference (p = 0.032).

Conclusion: There is an increase in PAI-1 levels in patients with NAFLD. PAI-1 levels have an independent effect on the degree of liver fibrosis in patients with NAFLD.

Note: This article has supplementary file(s).

Fulltext View|Download |  Cover Letter
Cover Letter
Subject
Type Cover Letter
  Download (17KB)    Indexing metadata
 Copyright Transfer Agreement
Conflict of Interest and CTA
Subject
Type Copyright Transfer Agreement
  Download (378KB)    Indexing metadata
 Research Instrument
Ethical Clearance
Subject
Type Research Instrument
  Download (808KB)    Indexing metadata
Keywords: NAFLD; NASH; PAI-1; liver fibrosis

Article Metrics:

Article Info
Section: Original Research Articles
Language : EN
Recent articles
Increased Level of The Plasminogen Activator Inhibitor Type-1 is Associated with Severity of NAFLD Effect Of Zinc Administration in Preventing Ethambutol-Induced Optic Neuropathy in Wistar Rats Model BALB/c Mice as Animal Model in Dengue Infection Research: Role of Endothelial Activation Plasma Exchange as A Rescue Therapy in Weil’s Disease with Severe Hyperbilirubinemia, Acute Renal Failure, And Multidrug-Resistant Organism Co-Infection: A Rare Case in Critical Care Setting Mechanism of Immune System Dysfunction, Apoptosis and Oxidative Stress on Endometriosis More recent articles
  1. Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med [Internet]. 2017;377(21):2063–72. Available from: http://dx.doi.org/10.1056/nejmra1503519
  2. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol [Internet]. 2018;15(1):11–20. Available from: http://dx.doi.org/10.1038/nrgastro.2017.109
  3. Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol [Internet]. 2020;72(6):1196–209. Available from: https://doi.org/10.1016/j.jhep.2020.02.020
  4. Ge X, Zheng L, Wang M, Du Y, Jiang J. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990-2017: a population-based observational study. BMJ Open. 2020;10(8):e036663
  5. Le MH, Devaki P, Ha NB et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12:e0173499
  6. Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GBB, et al. Modelling NAFLD disease burden in four Asian regions—2019-2030. Aliment Pharmacol Ther. 2020;51(8):801–11
  7. Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol [Internet]. 2022 Aug 21; Available from: https://doi.org/10.1016/j.cgh.2021.12.002
  8. Khammas ASA, Hassan HA, Salih SQM, Kadir H, Ibrahim RM, Nasir NNM, et al. Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study. Porto Biomed J. 2019;4(2):e31
  9. Targher G, Day CP BE. Current Concepts Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2010;363:1341–50
  10. Purnomo HD, Kasno, Sudijanto E, Hirlan, Darmono, Daldiyono, et al. The roles of metabolic syndrome and several biomarkers in incidence and severity of non-alcoholic fatty liver disease. Hiroshima J Med Sci. 2018;67(4):138–46
  11. Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol [Internet]. 2021;110(7):921–37. Available from: https://doi.org/10.1007/s00392-020-01709-7
  12. Henkel AS, Khan SS, Olivares S, Miyata T, Vaughan DE. Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice. Hepatol Commun [Internet]. 2018;2(12):1479–92. Available from: http://dx.doi.org/10.1002/hep4.1259
  13. Jin R, Krasinskas A, Le NA, Konomi J V., Holzberg J, Romero R, et al. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease. Pediatr Obes [Internet]. 2018;13(1):23–9. Available from: http://dx.doi.org/10.1111/ijpo.12183
  14. Alsharoh H, Ismaiel A, Leucuța DC, Popa SL, Dumitrascu DL. Plasminogen Activator Inhibitor-1 Levels in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. J Gastrointest Liver Dis. 2022;31(2):206–14
  15. Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol [Internet]. 2020;16(3):177–89. Available from: http://dx.doi.org/10.1038/s41574-019-0310-7
  16. Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract [Internet]. 2020;35(1):72–84. Available from: http://dx.doi.org/10.1002/ncp.10449
  17. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr [Internet]. 2020;12(1):1–20. Available from: https://doi.org/10.1186/s13098-020-00570-y
  18. Kühn T, Nonnenmacher T, Sookthai D, Schübel R, Quintana Pacheco DA, von Stackelberg O, et al. Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. BMC Gastroenterol [Internet]. 2018;18(1):1–9. Available from: http://dx.doi.org/10.1186/s12876-018-0840-9
  19. Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ - Linking NAFLD and Insulin Resistance. Endocr Rev [Internet]. 2019;40(5):1367–93. Available from: http://dx.doi.org/10.1210/er.2019-00034
  20. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci [Internet]. 2016;13(1):25–38. Available from: http://dx.doi.org/10.7150/ijms.13800
  21. Jung RG, Motazedian P, Ramirez FD, Simard T, Di Santo P, Visintini S, et al. Association between plasminogen activator inhibitor-1 and cardiovascular events: A systematic review and meta-analysis. Thromb J [Internet]. 2018;16(1):1–12. Available from: http://dx.doi.org/10.1186/s12959-018-0166-4
  22. Sakurai S, Jojima T, Iijima T, Tomaru T, Usui I, Aso Y. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis. J Diabetes Complications [Internet]. 2020;34(11):107703. Available from: https://doi.org/10.1016/j.jdiacomp.2020.107703

Last update:

No citation recorded.

Last update:

No citation recorded.